This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCampbell, A. S. Articles by Davies, P. J.A. Search for Related Content PubMed PubMed Citation Articles by McCampbell, A. S. Articles by Davies, P. J.A. Related Collections Commentary

Overexpression of the Insulin-Like Growth Factor I Receptor and Activation of the AKT Pathway in Hyperplastic Endometrium

Authors' Affiliations: ¹ Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas and ² Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Peter J.A. Davies, Department of Integrative Biology and Pharmacology, University of Texas Houston Health Science Center, MSB 5.104, 6431 Fannin Street, Houston, TX 77030. Phone: 713-500-3082; Fax: 713-500-7455; E-mail: Peter.J.Davies{at}uth.tmc.edu.

Purpose: Although there is considerable information on the molecular aberrations associated with endometrial cancer, very little is known of the changes in gene expression associated with endometrial hyperplasia.

Experimental Design: To address this, we have compared the level of expression of estrogen-regulated genes and components of the insulin-like growth factor I (IGF-I) signaling pathway in endometrial biopsies from subjects with normal endometrium, complex atypical endometrial hyperplasia, and endometrial adenocarcinoma (type I).

Results: There was a significant increase in the expression of the IGF-I receptor (IGF-IR) in biopsies from hyperplastic endometrium and endometrial carcinoma compared with the proliferative endometrium. The receptor was also activated, as judged by increased tyrosine phosphorylation. In addition, in endometrial hyperplasia and carcinoma, the downstream components of the IGF-IR pathway are activated, as reflected in increased Akt phosphorylation. Loss of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) expression in endometrial hyperplasia did not correlate with increased activation of IGF-IR. However, the simultaneous loss of PTEN expression and increased IGF-IR activation in hyperplasia was associated with an increased incidence of endometrial carcinoma.

Conclusions: These results suggest that up-regulation of IGF-IR and loss of PTEN may be independent events that give rise to complementary activation of the IGF-I pathway and increase the probability of the development of cancer. These studies suggest that increased expression of IGF-IR may be an important contributor to the risk of endometrial hyperplasia and cancer.

Commentary

Is the Type I Insulin-Like Growth Factor Receptor a Therapeutic Target in Endometrial Cancer?

Hua Zhang and Douglas Yee
Clin. Cancer Res. 2006 12: 6323-6325. [Full Text] [PDF]

This article has been cited by other articles:

				P. Laudanski, J. Szamatowicz, O. Kowalczuk, M. Kuzmicki, M. Grabowicz, and L. Chyczewski Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis Hum. Reprod., May 8, 2009; (2009) dep175v1. [Abstract] [Full Text] [PDF]

				S. C. J. P. Gielen, L. A. M. Santegoets, L. C. M. Kuhne, W. F. J. Van IJcken, B. Boers-Sijmons, P. Hanifi-Moghaddam, T. J. M. Helmerhorst, L. J. Blok, and C. W. Burger Genomic and Nongenomic Effects of Estrogen Signaling in Human Endometrial Cells: Involvement of the Growth Factor Receptor Signaling Downstream AKT Pathway Reproductive Sciences, October 1, 2007; 14(7): 646 - 654. [Abstract] [PDF]

				E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s. [Abstract] [Full Text] [PDF]